Astellas Pharma Global Development Inc.

• A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Ca… Pending
  2024-520286-31-00 Phase I (Other) 1 country
• A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) Recruiting
  2025-522398-12-00 Phase I (Other) 2 countries
• A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea… Recruiting
  2022-501980-42-00 Phase III 20 countries ROXADUSTAT
• A study to find a suitable dose of ASP5834 in adults with solid tumors Recruiting
  2025-522082-29-00 Phase I 2 countries
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting
  2024-517653-27-00 Phase II 5 countries ABIRATERONE DECANOATE
• A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or… Recruiting
  2023-504514-29-00 Phase I 3 countries
• A study of ASP3082 in adults with advanced solid tumors Recruiting
  2022-501590-39-00 Phase I 2 countries
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended
  2024-519773-19-00 Phase III 11 countries PEMBROLIZUMAB; ZOLBETUXIMAB
• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended
  2024-510719-31-00 Phase III 9 countries FEZOLINETANT
• A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites Ended
  2022-500660-35-00 Phase I 1 country
• A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended
  2024-510985-17-00 Phase II 4 countries ZOLBETUXIMAB
• A Study of Zolbetuximab (IMAB362) plus CAPOX in Adults with Gastric Cancer. Ended
  2024-511648-16-00 Phase III 3 countries SODIUM CHLORIDE; ZOLBETUXIMAB
• A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus… Ended
  2024-511365-11-00 Phase III 6 countries SODIUM CHLORIDE; ZOLBETUXIMAB
• A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination with Chemotherapy and/or Immunotherapy in Subjects with Metastat… Ended
  2024-511649-21-00 Phase II 2 countries FLUOROURACIL; FOLINIC ACID; NIVOLUMAB; OXALIPLATIN; ZOLBETUXIMAB
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended
  2023-510298-33-00 Phase II 15 countries ENZALUTAMIDE
• A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together with Either Pembrolizumab, Standard Therapies, or Both, in Adults with Solid T… Ended
  2023-505084-37-00 Phase I (FiH) 2 countries ASP1570; PEMBROLIZUMAB
• A study to learn how effective and safe the drug “mirabegron” is and how long it stays in the body of children aged 6 months to less than 3 … Ended
  2023-507903-74-00 Phase III 4 countries MIRABEGRON
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 Phase III 10 countries AVACINCAPTAD PEGOL
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid… Ended
  2024-512469-15-00 Phase I/II 4 countries CYTARABINE; FILGRASTIM; FLUDARABINE PHOSPHATE; GILTERITINIB
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelia… Ended
  2024-517571-20-00 Phase III 2 countries ENFORTUMAB VEDOTIN
• A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone… Ended
  2024-512474-98-00 Phase III 2 countries AZACITIDINE; GILTERITINIB
• A trial to compare the levels of the active ingredient tacrolimus in the blood of patients before and after switching between the Prograf an… Ended
  2024-513546-11-00 Phase II 1 country TACROLIMUS

Showing 1–22 of 22 trials